Possible neuropsychiatric reaction to high-dose oseltamivir during acute 2009 H1N1 influenza a infection

Clinical Infectious Diseases

Volumn 50, Issue 7, 2010, Pages

  Nakamura, Kenta ^a   Schwartz, Brian S ^b   Lindegårdh, Niklas ^c   Keh, Chris ^b   Guglielmo, B Joseph ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ACICLOVIR; CEFEPIME; DOCUSATE SODIUM; ELECTROLYTE; ENTECAVIR; HEPARIN; OSELTAMIVIR; PANTOPRAZOLE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTERIAL GAS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FEVER; HUMAN; HYPOXIA; INFLUENZA; INFLUENZA VIRUS A H1N1; MALE; MENTAL HEALTH; NEUROPSYCHIATRY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; SENNA; SINUS CONGESTION; SINUSITIS; SPHENOID SINUS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VISUAL HALLUCINATION;

ADULT; ANTIVIRAL AGENTS; CONFUSION; HALLUCINATIONS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; NEUROTOXICITY SYNDROMES; OSELTAMIVIR; TRANSPLANTATION, AUTOLOGOUS;

EID: 77749326569     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/651166     Document Type: Article

References (16)

1. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999;282(13): 1240-1246.
2. Treanor JJ, Hayden FG, Vrooman PS, et al; US Oral Neuraminidase Study Group. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000; 283(8):1016-1024.
3. WHO Guidelines for Pharmacological Management of Pandemic (H1N1) 2009 Influenza and other Influenza Viruses, http://www.who.int/csr/resources/ publications/swineflu/h1n1-guidelines-pharmaceutical-mngt.pdf. Accessed 20 August 2009.
4. Morishima T, Togashi T, Yokota S, et al. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect Dis 2002; 35(5):512-517.
5. Centers for Disease Control and Prevention (CDC). Neurologic complications associated with novel influenza A (H1N1) virus infection in children-Dallas, Texas, May 2009. MMWR Wkly Rep 2009; 58(28): 773-778.
6. Hama R. Fatal neuropsychiatric adverse reactions to oseltamivir: case series and overview of causal relationships. Int J Risk Safety Med 2008; 20(1-2):5-36.
7. Edwards ET, Truffa MM, Mosholder AD. Postmarketing safety evaluator: Division of Drug Risk Evaluation (DDRE). Silver Spring, MD: US Food and Drug Administration, Center for Drug Evaluation and Research, 2006.
8. Hama R. Oseltamivir's adverse reactions: fifty sudden deaths may be related to central suppression. BMJ 2007; 335(7610):59.
9. Wattanagoon Y, Stepniewska K, Lindegardh N, et al. Pharmacokinetics of high-dose oseltamivir in healthy volunteers. Antimicrob Agents Chemother 2009; 53(3):945-952.
10. 10. Lindegardh N, Davies GR, Tran TH, et al. Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases. Antimicrob Agents Chemother 2006; 50(9):3197-3199. (Pubitemid 44396439)
11. Toovey S, Rayner C, Prinssen E, et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 2008; 31 (12): 1097-1114.
12. Smith JR, Sacks S. Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment. Int J Clin Pract 2009; 63(4):596-605.
13. 13. Izumi Y, Tokuda K, O'Dell K A, Zorumski CF, Narahashi T. Neuroexcitatory actions of Tamiflu and its carboxylate metabolite. Neurosci Lett 2007; 426(1):54-58. (Pubitemid 47444506)
14. 14. Li CY, Yu Q, Ye ZQ, et al. A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivir. Cell Res 2007; 17(4):357-362. (Pubitemid 46639940)
15. 15. Schentag JJ, Hill G, Chu T, Rayner CR. Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects. J Clin Pharmacol 2007; 47(6) :689-696. (Pubitemid 46800424)
16. 16. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999; 37(6):471-484. (Pubitemid 30032251)